| Literature DB >> 28944125 |
Faizan Yasin1, Salman Assad2, Mehr Zahid3, Shuja A Malik4.
Abstract
Pyoderma gangrenosum is a very rare, non-infectious leukocytic dermatosis, which is often associated with an underlying systemic disease. It is usually diagnosed based on the apparent clinical findings and by excluding other causes of ulcerative skin diseases. Treatment modality includes the use of systemic steroids and oral steroids. Immunosuppressive agents, such as cyclosporine and mycophenolate mofetil, can also be added if it fails to respond to steroids. We report a case of pyoderma gangrenosum in an 85-year-old female who presented in the inpatient facility with rapidly enlarging necrotic, ulcerative lesions with accompanying fever. She was managed with systemic steroids to which she responded well. This led to the arrest of the initially progressive lesions with some residual scarring.Entities:
Keywords: corticosteroids; healing; pathergy; pyoderma gangrenosum
Year: 2017 PMID: 28944125 PMCID: PMC5602483 DOI: 10.7759/cureus.1486
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Clinical findings
(A, B) Ulcers having a purulent base, asymmetrical borders, and erythematous surrounding. (C) A large ulcerative lesion having a purulent base with purple raised borders and erythematous surrounding. (D) Ulcer base covered with granulation tissue. The top layer of skin missing
Figure 2Aphthous ulcer on the lower labial mucosa
Complete Blood Count (CBC) with Differential
WBC: white blood cell; RBC: red blood cell; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; MPV: mean platelet volume; RDW: red cell distribution width
|
|
|
|
|
| BLOOD COMPLETE PICTURE | |||
| WBC Count | 14.52 | 4 - 11 | 10^3/uL |
| RBC Count | 3.65 | 4 - 5.2 | 10^6/uL |
| Hemoglobin | 10.7 | 11.5 - 16 | g/dL |
| HCT | 31.1 | 33 - 45 | % |
| MCV | 85.2 | 79 - 95 | fL |
| MCH | 29.3 | 26 - 32 | pg |
| MCHC | 34.4 | 32 - 36 | g/dL |
| Platelets | 468 | 150 - 450 | 10^3/uL |
| MPV | 10.9 | 7.2 - 13 | fL |
| RDW | 14.2 | 11.5 - 14.5 | % |
| DIFFERENTIAL COUNT | |||
| Neutrophils | 85 | 34 - 70 | % |
| Lymphocytes | 10 | 19 - 52 | % |
| Monocytes | 3 | 2 - 12 | % |
| Eosinophils | 2 | 1 - 6 | % |
Inflammatory Markers
|
|
|
|
| Erythrocyte Sedimentation Rate (ESR) | 91 | 0 - 20 |
| C-reactive protein (CRP) | 192 | < 5 |
| Rheumatoid Factor (RF) | 5 | < 30 IU/mL – Negative 30 - 50 IU/mL – Weak Positive > 50 IU/mL – Positive |
| Anti-nuclear antibody (ANA) | Negative | Negative |
Coagulation Profile
|
|
|
|
|
| Prothrombin Time (PT) | |||
| Patient Value | 11.7 | 9 - 14 | SEC |
| Control Value | 10.2 | SEC | |
| International Normalized Ratio (INR) | 1.15 | ||
| Activated Partial Thromboplastin Time (APTT) | |||
| Patient Value | 28.0 | 22 - 31 | SEC |
| Control Value | 26.4 | SEC |
Complete Blood Count (CBC) with Differential
RDW: red cell distribution width
WBC: white blood cell; RBC: red blood cell; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW: red cell distribution width
|
|
|
|
|
| BLOOD COMPLETE PICTURE | |||
| WBC Count | 17 | 4 - 11 | 10^3/uL |
| RBC Count | 4.04 | 4 - 5.2 | 10^6/uL |
| Hemoglobin | 11.7 | 11.5 - 16 | g/dL |
| HCT | 36 | 33 - 45 | % |
| MCV | 89 | 79 - 95 | fL |
| MCH | 29 | 26 - 32 | pg |
| MCHC | 32 | 32 - 36 | g/dL |
| Platelets | 415 | 150 - 450 | 10^3/uL |
| RDW | 12.2 | 11.5 - 14.5 | % |
| DIFFERENTIAL COUNT | |||
| Neutrophils | 80 | 34 - 70 | % |
| Lymphocytes | 14 | 19 - 52 | % |
| Monocytes | 4 | 2 - 12 | % |
| Eosinophils | 2 | 1 - 6 | % |
Laboratory Findings
|
|
|
|
|
| Alanine Aminotransferase (ALT) | 21 | 5 - 31 | u/L |
| Serum Creatinine | 0.7 | 0.5 - 0.9 | mg/dL |
| Glycosylated Hemoglobin (HbA1c) | 5.7 | 4.8 - 5.9 | % |
| Interpretation | Non-Diabetic: < 5.9% Prediabetic: 5.9 – 6.4% Diabetic: >/= 6.5% | ||
Figure 3Histopathology
(A, B) Surface ulceration. (C, D) The adjacent dermis shows acute and chronic inflammation. Neutrophilic infiltrate (red arrows) indicates acute inflammation, plus neovascularization seen (blue arrow). (E, F) Fibroblast proliferation (green arrow). Lymphocytic infiltrate indicating chronic inflammation (yellow arrows)
Figure 4Ulcers with asymmetrical borders, residual scarring and necrosis. Base of ulcers covered with granulation tissue
Further Laboratory Investigations
|
|
|
|
|
| Blood Urea Nitrogen (BUN) | 47 | 10 - 50 | mg/dL |
| Serum Creatinine | 0.7 | 0.5 - 0.9 | mg/dL |
| Blood Sugar (Random) | 114 | < 140 | mg/dL |
| Sodium (Na) | 133 | 132 - 146 | mmol/L |
| Potassium | 4.3 | 3.3 - 5.1 | mmol/L |
| Liver Function Tests | |||
| Total Bilirubin | 0.5 | 0.1 - 1.0 | mg/dL |
| Alanine aminotransferase (ALT) | 34 | 5 - 31 | u/L |
| Aspartate aminotransferase (AST) | 16 | 5 - 32 | u/L |
| Alkaline Phosphatase (ALP) | 196 | 35 - 104 | u/L |
| Serum Total Protein | 6.1 | 6.4 - 8.3 | g/dL |
| Serum Albumin | 2.0 | 3.4 - 4.8 | g/dL |
| Gamma Glutamyl Transferase (GGT) | 103 | 7 - 32 | u/L |